Incyte Stock Price

-1.17 (-1.55%)
Upgrade to Real-Time
Regular Market
Volume 1,196,192
Bid Price 74.17
Ask Price 74.20
News -
Day High 75.04


52 Week Range


Day Low 72.67
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Incyte Corporation INCY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.17 -1.55% 74.17 15:57:44
Open Price Low Price High Price Close Price Prev Close
74.79 72.67 75.04 75.34
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
19,947 1,196,192 $ 74.19 $ 88,746,272 - 61.91 - 101.47
Last Trade Time Type Quantity Stock Price Currency
15:57:43 1 $ 74.17 USD


Draw Mode:

Incyte Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 16.38B 220.89M 155.27M $ 2.67B $ 483.21M -1.39 30.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 15.58k 1.50%

more financials information »

Incyte News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical INCY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week75.7176.5072.6775.012,207,442-1.54-2.03%
1 Month73.8576.5070.3773.891,973,2490.320.43%
3 Months65.5476.5061.9169.762,367,8948.6313.17%
6 Months78.7780.3061.9170.371,862,693-4.60-5.84%
1 Year98.91101.4761.9175.361,552,047-24.74-25.01%
3 Years77.40111.0561.9181.901,399,266-3.23-4.17%
5 Years119.13153.1557.0088.531,574,922-44.96-37.74%

Incyte Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.